Geode Capital Management’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-478,208
| Closed | -$395K | – | 4487 |
|
|
2025
Q1 | $395K | Buy |
478,208
+16,940
| +4% | +$16.3K | ﹤0.01% | 3633 |
|
|
2024
Q4 | $438K | Buy |
461,268
+7,768
| +2% | +$7.33K | ﹤0.01% | 3641 |
|
|
2024
Q3 | $454K | Sell |
453,500
-5,788
| -1% | -$6.41K | ﹤0.01% | 3619 |
|
|
2024
Q2 | $570K | Buy |
459,288
+18,063
| +4% | +$18.4K | ﹤0.01% | 3523 |
|
|
2024
Q1 | $574K | Buy |
441,225
+12,703
| +3% | +$14.5K | ﹤0.01% | 3561 |
|
|
2023
Q4 | $536K | Buy |
428,522
+18,205
| +4% | +$20.1K | ﹤0.01% | 3590 |
|
|
2023
Q3 | $534K | Buy |
410,317
+11,605
| +3% | +$18.8K | ﹤0.01% | 3579 |
|
|
2023
Q2 | $686K | Sell |
398,712
-369,887
| -48% | -$587K | ﹤0.01% | 3502 |
|
|
2023
Q1 | $1.12M | Buy |
768,599
+26,087
| +4% | +$50K | ﹤0.01% | 3294 |
|
|
2022
Q4 | $1.2M | Buy |
742,512
+6,939
| +0.9% | +$16K | ﹤0.01% | 3268 |
|
|
2022
Q3 | $2.46M | Sell |
735,573
-11,409
| -2% | -$51.5K | ﹤0.01% | 3014 |
|
|
2022
Q2 | $2.72M | Buy |
746,982
+21,559
| +3% | +$97.7K | ﹤0.01% | 3008 |
|
|
2022
Q1 | $5.24M | Sell |
725,423
-3,725
| -0.5% | -$31.8K | ﹤0.01% | 2772 |
|
|
2021
Q4 | $9.91M | Buy |
729,148
+3,540
| +0.5% | +$55.4K | ﹤0.01% | 2455 |
|
|
2021
Q3 | $15.2M | Buy |
725,608
+254,585
| +54% | +$5.47M | ﹤0.01% | 2152 |
|
|
2021
Q2 | $11.3M | Buy |
471,023
+202,103
| +75% | +$5.12M | ﹤0.01% | 2378 |
|
|
2021
Q1 | $7.87M | Buy |
268,920
+17,278
| +7% | +$506K | ﹤0.01% | 2518 |
|
|
2020
Q4 | $7.52M | Buy |
+251,642
| New | +$7.89M | ﹤0.01% | 2349 |
|
Geode Capital Management's KRON Position: Q2 2025 in Review
Geode Capital Management sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 478,208 shares — an estimated $395K sold.
Geode Capital Management first reported a position in KRON in Q4 2020 and held it in 18 quarters. The position peaked at $15.2M in Q3 2021. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Geode Capital Management reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Geode Capital Management sold 478,208 Kronos Bio shares in Q2 2025, an estimated $395K.
- Geode Capital Management first reported a position in Kronos Bio in Q4 2020 and held it in 18 quarters.
- Geode Capital Management's Kronos Bio position peaked at $15.2M in Q3 2021.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Geode Capital Management's 13F filing for Q2 2025, filed 8 Aug 2025.